top of page

NovoBind begins fundraising to commercialize it's nanobody platform

Canadian start-up Novobind Livestock Therapeutics has started raising investment to support the development of its nanobody-based biologics.


The firm’s platform produces nanobodies derived from the VHH domain of llama heavy chain-only antibodies for animal feed applications. The Vancouver-based company is working on nanobody-based biologics (called NBXs) designed to neutralize key pathogens affecting poultry and shrimp.


Download Article Below


Novobind_begins_fundraising_to_commercialize_its_nanobody_platform
.pdf
Download PDF • 165KB

Comments


bottom of page